REGISTERED NUMBER: |
UNAUDITED FINANCIAL STATEMENTS |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
FOR |
LONDON LABORATORY LTD |
REGISTERED NUMBER: |
UNAUDITED FINANCIAL STATEMENTS |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
FOR |
LONDON LABORATORY LTD |
LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592) |
CONTENTS OF THE FINANCIAL STATEMENTS |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
Page |
Company Information | 1 |
Statement of Financial Position | 2 |
Notes to the Financial Statements | 3 |
LONDON LABORATORY LTD |
COMPANY INFORMATION |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
DIRECTORS: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Business Advisers and Accountants |
Unit 2.02 High Weald House, |
Glovers End |
Bexhill |
East Sussex |
United Kingdom |
TN39 5ES |
LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592) |
STATEMENT OF FINANCIAL POSITION |
31 AUGUST 2023 |
Notes | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
CURRENT ASSETS |
Stocks | 5 |
Debtors | 6 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 7 |
NET CURRENT LIABILITIES | ( |
) |
TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
CAPITAL AND RESERVES |
Called up share capital | 8 |
Share premium |
Retained Losses | ( |
) |
SHAREHOLDERS' FUNDS | ( |
) |
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered. |
The financial statements were approved by the Board of Directors and authorised for issue on |
LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592) |
NOTES TO THE FINANCIAL STATEMENTS |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
1. | STATUTORY INFORMATION |
London Laboratory Ltd is a |
The presentation currency of the financial statements is the Pound Sterling (£). |
2. | ACCOUNTING POLICIES |
BASIS OF PREPARING THE FINANCIAL STATEMENTS |
SIGNIFICANT JUDGEMENTS AND ESTIMATES |
In preparing the financial statements, the directors are required to make estimates and judgments about thecarrying amounts of assets and liabilities. The estimates and assumptions are reviewed on an ongoing basis andare based on historical experience and other factors that are considered by the directors to be relevant. Revision to accounting estimates are recognised in the period in which the estimate is revised. |
TURNOVER |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
TANGIBLE FIXED ASSETS |
Plant and machinery | - |
Computer equipment | - |
STOCKS |
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
2. | ACCOUNTING POLICIES - continued |
FINANCIAL INSTRUMENTS |
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. |
Financial instruments are recognized in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. |
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognized amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. |
Basic financial assets |
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortized cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortized. |
Classification of financial liabilities |
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. |
Basic financial liabilities |
Basic financial liabilities, including creditors, bank loans and loans from fellow group companies that are classified as debt, are initially recognized at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payment discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortized. |
Debt instruments are subsequently carried at amortized cost, using the effective interest rate method. |
TAXATION |
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date. |
DEFERRED TAX |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS |
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
2. | ACCOUNTING POLICIES - continued |
GOING CONCERN |
The company's balance sheet shows net deficit shareholders fund position at the end of the period. However, the directors have received confirmation from the shareholders of their continued financial support for the foreseeable future.and for at least twelve months from the date of signature of these accounts. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the period was |
4. | TANGIBLE FIXED ASSETS |
Plant and | Computer |
machinery | equipment | Totals |
£ | £ | £ |
Cost |
Additions |
At 31 August 2023 |
Depreciation |
Charge for period |
At 31 August 2023 |
Net book value |
At 31 August 2023 |
5. | STOCKS |
£ |
Stocks |
6. | DEBTORS |
£ |
Amounts falling due within one year: |
Trade debtors |
Other debtors |
Amounts falling due after more than one year: |
Deferred tax asset |
Aggregate amounts |
LONDON LABORATORY LTD (REGISTERED NUMBER: 14281592) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE PERIOD 8 AUGUST 2022 TO 31 AUGUST 2023 |
7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
£ |
Social security |
Trade creditors |
Amounts owed to group undertakings |
Other creditors |
8. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal |
value: | £ |
Ordinary | £.01 | 10 |
1,040 Ordinary shares of £.01 each were allotted as fully paid |
9. | POST BALANCE SHEET EVENTS |
Subsequent to the reporting date but before the approval of these financial statements, there has been a significant change in the ownership structure of the Company. As at 06 September 2023, Jorja Healthcare Holdings Ltd has acquired 100% share capital of the Company. |
This change in shareholding occurred after the balance sheet date but is deemed to be a non-adjusting event. The impact of this change on the financial position and results of operations is not reflected in these financial statements. |